Synthesis and evaluation of osimertinib derivatives as potent EGFR inhibitors

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Osimertinib is a key therapeutic for EGFR T790M mutant non-small cell lung cancer (NSCLC).
• Developing novel derivatives with improved efficacy and selectivity is crucial for advancing lung cancer treatment.

Purpose of the Study:

• To design and synthesize novel N-oxidized and fluorinated osimertinib derivatives.
• To evaluate the in vitro and in vivo anti-cancer activities of these derivatives.
• To identify potential new drug candidates for EGFR-mutated NSCLC.

Main Methods:

• Synthesis of N-oxidized and fluorinated osimertinib derivatives.
• In vitro assessment of cellular anti-proliferative and kinase inhibitory activity against EGFR variants.
• In vivo evaluation of antitumor efficacy using NCI-H1975 xenograft models.

Main Results:

• Compound 2, an N-oxide metabolite, exhibited comparable kinase selectivity to osimertinib in vitro.
• Compound 2 demonstrated slightly enhanced antitumor efficacy in vivo compared to osimertinib.
• The synthesized derivatives were evaluated for their potential as lung cancer therapeutics.

Conclusions:

• The novel N-oxide derivative (Compound 2) shows promise as a potential therapeutic agent for non-small cell lung cancer.
• Compound 2's comparable in vitro activity and improved in vivo efficacy warrant further investigation for clinical application.
• This study contributes to the development of next-generation EGFR inhibitors for NSCLC treatment.